Checkpoint Sale Purchase Of Stock vs Begin Period Cash Flow Analysis

CKPT Stock

USD 3.93 0.04 1.01%

Checkpoint Therapeutics financial indicator trend analysis is way more than just evaluating Checkpoint Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Checkpoint Therapeutics is a good investment. Please check the relationship between Checkpoint Therapeutics Sale Purchase Of Stock and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Checkpoint Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.

Sale Purchase Of Stock vs Begin Period Cash Flow

Sale Purchase Of Stock vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Checkpoint Therapeutics Sale Purchase Of Stock account and Begin Period Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between Checkpoint Therapeutics' Sale Purchase Of Stock and Begin Period Cash Flow is -0.82. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Checkpoint Therapeutics, assuming nothing else is changed. The correlation between historical values of Checkpoint Therapeutics' Sale Purchase Of Stock and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of Checkpoint Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Sale Purchase Of Stock i.e., Checkpoint Therapeutics' Sale Purchase Of Stock and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.82

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Sale Purchase Of Stock

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Checkpoint Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Checkpoint Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Checkpoint Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.Sales General And Administrative To Revenue is likely to gain to 88.54 in 2024, whereas Selling General Administrative is likely to drop slightly above 7.3 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	53K	4.5M	167.9K	159.5K
Interest Income	53K	160K	154K	102.1K

Depreciation And Amortization Interest Income

Checkpoint Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Short Long Term Debt Total	Net Debt	Cash And Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse
Total Assets		0.1	0.28	0.86	0.73	-0.12	0.44	1.0	0.22	0.31	-0.38	-0.61	0.68	0.46	0.35	0.31	0.63	1.0	0.63	0.75	0.26	-0.17	0.13	0.26	0.33	0.27
Other Current Liab	0.1		0.95	-0.39	0.47	-0.83	0.68	0.1	-0.12	0.79	-0.84	0.3	0.53	0.38	0.85	0.94	0.53	0.1	0.53	0.27	-0.25	0.57	-0.59	-0.25	0.72	0.87
Total Current Liabilities	0.28	0.95		-0.24	0.5	-0.83	0.88	0.27	0.07	0.83	-0.9	0.18	0.63	0.49	0.87	1.0	0.63	0.28	0.63	0.48	-0.23	0.52	-0.55	-0.23	0.73	0.88
Total Stockholder Equity	0.86	-0.39	-0.24		0.46	0.34	-0.01	0.87	0.19	-0.14	0.1	-0.74	0.35	0.22	-0.11	-0.21	0.29	0.86	0.29	0.51	0.43	-0.46	0.44	0.43	-0.03	-0.18
Net Tangible Assets	0.73	0.47	0.5	0.46		-0.57	0.41	0.74	0.04	0.67	-0.65	-0.12	0.86	0.35	0.69	0.54	0.85	0.73	0.85	0.58	-0.24	0.34	-0.36	-0.24	0.27	0.56
Retained Earnings	-0.12	-0.83	-0.83	0.34	-0.57		-0.67	-0.11	0.07	-0.98	0.94	-0.52	-0.66	-0.39	-0.93	-0.83	-0.71	-0.12	-0.71	-0.51	0.66	-0.74	0.76	0.66	-0.37	-0.89
Accounts Payable	0.44	0.68	0.88	-0.01	0.41	-0.67		0.42	0.39	0.71	-0.8	-0.04	0.67	0.61	0.72	0.88	0.66	0.44	0.66	0.64	-0.16	0.42	-0.45	-0.16	0.54	0.7
Cash	1.0	0.1	0.27	0.87	0.74	-0.11	0.42		0.19	0.31	-0.37	-0.6	0.67	0.43	0.34	0.3	0.62	1.0	0.62	0.74	0.26	-0.19	0.15	0.26	0.33	0.26
Net Receivables	0.22	-0.12	0.07	0.19	0.04	0.07	0.39	0.19		-0.03	0.01	-0.44	0.34	0.29	-0.01	0.07	0.31	0.22	0.31	0.13	0.12	0.25	-0.26	0.12	-0.28	-0.12
Common Stock Total Equity	0.31	0.79	0.83	-0.14	0.67	-0.98	0.71	0.31	-0.03		-0.98	0.37	0.76	0.48	0.94	0.83	0.81	0.31	0.81	0.67	-0.6	0.68	-0.7	-0.6	0.41	0.89
Retained Earnings Total Equity	-0.38	-0.84	-0.9	0.1	-0.65	0.94	-0.8	-0.37	0.01	-0.98		-0.26	-0.76	-0.57	-0.96	-0.9	-0.79	-0.38	-0.79	-0.7	0.44	-0.6	0.63	0.44	-0.55	-0.93
Common Stock Shares Outstanding	-0.61	0.3	0.18	-0.74	-0.12	-0.52	-0.04	-0.6	-0.44	0.37	-0.26		-0.23	-0.37	0.27	0.17	-0.12	-0.61	-0.12	-0.19	-0.77	0.34	-0.32	-0.77	-0.06	0.34
Inventory	0.68	0.53	0.63	0.35	0.86	-0.66	0.67	0.67	0.34	0.76	-0.76	-0.23		0.65	0.78	0.65	0.99	0.68	0.99	0.71	-0.23	0.6	-0.63	-0.23	0.2	0.63
Other Current Assets	0.46	0.38	0.49	0.22	0.35	-0.39	0.61	0.43	0.29	0.48	-0.57	-0.37	0.65		0.52	0.48	0.62	0.46	0.62	0.62	0.1	0.39	-0.42	0.1	0.31	0.46
Other Stockholder Equity	0.35	0.85	0.87	-0.11	0.69	-0.93	0.72	0.34	-0.01	0.94	-0.96	0.27	0.78	0.52		0.87	0.77	0.35	0.77	0.62	-0.38	0.62	-0.65	-0.38	0.48	0.97
Total Liab	0.31	0.94	1.0	-0.21	0.54	-0.83	0.88	0.3	0.07	0.83	-0.9	0.17	0.65	0.48	0.87		0.65	0.31	0.65	0.48	-0.23	0.52	-0.54	-0.23	0.73	0.87
Short Long Term Debt	0.63	0.53	0.63	0.29	0.85	-0.71	0.66	0.62	0.31	0.81	-0.79	-0.12	0.99	0.62	0.77	0.65		0.63	1.0	0.71	-0.37	0.65	-0.68	-0.37	0.16	0.62
Total Current Assets	1.0	0.1	0.28	0.86	0.73	-0.12	0.44	1.0	0.22	0.31	-0.38	-0.61	0.68	0.46	0.35	0.31	0.63		0.63	0.75	0.26	-0.17	0.13	0.26	0.33	0.27
Short Term Debt	0.63	0.53	0.63	0.29	0.85	-0.71	0.66	0.62	0.31	0.81	-0.79	-0.12	0.99	0.62	0.77	0.65	1.0	0.63		0.71	-0.37	0.65	-0.68	-0.37	0.16	0.62
Common Stock	0.75	0.27	0.48	0.51	0.58	-0.51	0.64	0.74	0.13	0.67	-0.7	-0.19	0.71	0.62	0.62	0.48	0.71	0.75	0.71		-0.13	0.14	-0.19	-0.13	0.31	0.58
Short Long Term Debt Total	0.26	-0.25	-0.23	0.43	-0.24	0.66	-0.16	0.26	0.12	-0.6	0.44	-0.77	-0.23	0.1	-0.38	-0.23	-0.37	0.26	-0.37	-0.13		-0.63	0.63	1.0	0.26	-0.31
Net Debt	-0.17	0.57	0.52	-0.46	0.34	-0.74	0.42	-0.19	0.25	0.68	-0.6	0.34	0.6	0.39	0.62	0.52	0.65	-0.17	0.65	0.14	-0.63		-1.0	-0.63	-0.1	0.49
Cash And Short Term Investments	0.13	-0.59	-0.55	0.44	-0.36	0.76	-0.45	0.15	-0.26	-0.7	0.63	-0.32	-0.63	-0.42	-0.65	-0.54	-0.68	0.13	-0.68	-0.19	0.63	-1.0		0.63	0.08	-0.52
Long Term Debt Total	0.26	-0.25	-0.23	0.43	-0.24	0.66	-0.16	0.26	0.12	-0.6	0.44	-0.77	-0.23	0.1	-0.38	-0.23	-0.37	0.26	-0.37	-0.13	1.0	-0.63	0.63		0.26	-0.31
Non Current Liabilities Total	0.33	0.72	0.73	-0.03	0.27	-0.37	0.54	0.33	-0.28	0.41	-0.55	-0.06	0.2	0.31	0.48	0.73	0.16	0.33	0.16	0.31	0.26	-0.1	0.08	0.26		0.59
Capital Surpluse	0.27	0.87	0.88	-0.18	0.56	-0.89	0.7	0.26	-0.12	0.89	-0.93	0.34	0.63	0.46	0.97	0.87	0.62	0.27	0.62	0.58	-0.31	0.49	-0.52	-0.31	0.59

Click cells to compare fundamentals

Checkpoint Therapeutics Account Relationship Matchups

Checkpoint Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.0M	42.6M	55.7M	13.3M	5.4M	5.1M
Other Current Liab	4.2M	3.8M	9.8M	21.2M	11.9M	6.3M
Total Current Liabilities	8.1M	7.2M	26.0M	32.8M	18.4M	12.9M
Total Stockholder Equity	18.8M	35.4M	29.7M	(19.5M)	(13.0M)	(12.4M)
Net Tangible Assets	11.8M	18.8M	35.4M	29.7M	34.2M	26.1M
Retained Earnings	(120.1M)	(143.2M)	(199.9M)	(262.5M)	(314.3M)	(298.6M)
Accounts Payable	3.9M	3.4M	16.1M	11.5M	6.6M	7.2M
Cash	26.1M	40.8M	54.7M	12.1M	4.9M	4.7M
Net Receivables	26K	20K	17K	73K	65.7K	62.4K
Common Stock Total Equity	4K	6K	7K	9K	10.4K	10.9K
Retained Earnings Total Equity	(95.4M)	(120.1M)	(143.2M)	(199.9M)	(179.9M)	(170.9M)
Common Stock Shares Outstanding	3.5M	5.6M	7.6M	8.8M	18.7M	19.7M
Other Current Assets	863K	1.8M	976K	1.1M	450K	427.5K
Other Stockholder Equity	136.4M	173.9M	216.4M	243.0M	301.3M	150.7M
Total Liab	8.1M	7.2M	26.0M	32.8M	18.4M	13.2M
Total Current Assets	27.0M	42.6M	55.7M	13.3M	5.4M	5.1M
Accumulated Other Comprehensive Income	2.5M	4.6M	6.6M	1.9M	3.4M	3.3M
Common Stock	4K	6K	7K	9K	1K	4.2K
Net Debt	(26.1M)	(40.8M)	(54.7M)	(12.1M)	(4.9M)	(5.2M)
Cash And Short Term Investments	26.1M	40.8M	54.7M	12.1M	4.9M	4.7M
Liabilities And Stockholders Equity	27.0M	42.6M	55.7M	13.3M	5.4M	5.1M
Capital Surpluse	107.2M	139.0M	173.9M	223.0M	256.5M	133.0M
Net Invested Capital	18.8M	35.4M	29.7M	(19.5M)	(13.0M)	(12.4M)
Net Working Capital	18.8M	35.4M	29.7M	(19.5M)	(13.0M)	(12.4M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC